By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Veracyte said today that Medicare contractor Palmetto GBA has agreed to cover its Afirma Gene Expression Classifier for use in thyroid nodule diagnosis.

The coverage decision means that Veracyte's genomic test "is now accessible to 40 million Medicare patients nationwide," the company said.

The Afirma test is intended to determine whether inconclusive thyroid nodule results are benign or suspicious for cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.